Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Cancer Therapies02:49

Cancer Therapies

7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Cancer Survival Analysis01:21

Cancer Survival Analysis

328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
  1. Home
  3. Treatment Patterns And Clinical Outcomes In Patients With Egfr-mutated Non-small-cell Lung Cancer After Progression On Osimertinib.
  1. Home
  3. Treatment Patterns And Clinical Outcomes In Patients With Egfr-mutated Non-small-cell Lung Cancer After Progression On Osimertinib.

Related Experiment Video

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

3.9K

Treatment Patterns and Clinical Outcomes in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer After Progression

Nathaniel D Robinson1, Maureen E Canavan1, Peter L Zhan1

  • 1Yale University School of Medicine, New Haven, CT.

Clinical Lung Cancer
|October 27, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

For advanced EGFR-mutated NSCLC patients progressing on osimertinib, continuing osimertinib with chemotherapy in second-line treatment significantly improved progression-free and overall survival compared to other regimens.

Keywords:
Acquired resistanceChemotherapyNSCLCNon-small cell lung cancerTargeted therapy

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.9K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K

Related Experiment Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

3.9K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.9K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Optimal second-line treatment for advanced EGFR-mutated non-small-cell lung cancer (NSCLC) after osimertinib progression remains unknown.
  • Current practice patterns for subsequent therapies are diverse.

Purpose of the Study:

  • To assess treatment patterns in patients with EGFR-mutated NSCLC post-first-line osimertinib progression.
  • To evaluate the association between different second-line therapies and patient survival outcomes.

Main Methods:

  • Retrospective cohort study utilizing a deidentified, nationwide electronic health record database.
  • Analysis included 538 patients with available second-line treatment data after first-line osimertinib.

Main Results:

  • Second-line regimens varied, commonly including chemotherapy (65%), immune checkpoint inhibitors (37%), and EGFR tyrosine kinase inhibitors (44%).
  • Continuation of osimertinib with chemotherapy in 333 patients (performance status 0-2) showed superior progression-free survival (10.1 vs. 5.9 months) and overall survival (17.0 vs. 12.8 months) versus chemotherapy alone.
  • This benefit was most significant in patients with EGFR exon 19 deletions.

    • Conclusions:

    • A wide array of second-line treatments are employed following osimertinib progression in EGFR-mutated NSCLC.
    • Continuing osimertinib in combination with chemotherapy demonstrates improved progression-free and overall survival.